This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05003/identifier/chemspider/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n6http://linked.opendata.cz/resource/drugbank/drug/DB05003/identifier/bindingdb/
n8http://linked.opendata.cz/resource/drugbank/drug/DB05003/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05003/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05003/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05003
rdf:type
n3:Drug
n3:description
Imexon is a substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It belongs to the family of drugs called cyanoaziridine derivatives. Also called Amplimexon. Imexon is a cyanoaziridine derivative. Imexon is a thiol-binding small molecule which induces mitochondrial oxidation, a loss of membrane potential and cytochrome C, leading to apoptosis.
n3:generalReferences
# Evens AM, Prachand S, Shi B, Paniaqua M, Gordon LI, Gartenhaus RB: Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent. Clin Cancer Res. 2004 Feb 15;10(4):1481-91. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14977852
n3:group
investigational
n3:indication
Investigated for use/treatment in melanoma, multiple myeloma, ovarian cancer, pancreatic cancer, and solid tumors.
owl:sameAs
n13:DB05003
dcterms:title
Imexon
adms:identifier
n6:50073659 n8:68791 n9:11407098 n10:62031 n11:DB05003
n3:mechanismOfAction
Imexon enters the cell and binds to glutathione and other sulfhydryl compounds, effectively preventing them from scavenging the toxic free radicals. So, particularly in the rapidly dividing cancer cell, free radical build-up in the presence of imexon leads to changes in mitochondrial membrane potential and ultimately to the mitochondria swelling and bursting. Mitochondrial proteins, in particular cytochrome c, are released into the cytoplasm and this activates caspase-mediated apoptosis resulting in cancer cell death. This sequence of events has been well characterized and published in several papers in leading cancer journals. Imexon is probably the only cancer drug under development at this time which exploits this mechanism of action. Imexon is an inhibitor of ribonucleotide reductase, a key enzyme in DNA synthesis that is also a target for gemcitabine. Imexon is also a cell cycle inhibitor and in the presence of the drug cells accumulate in S phase.
n3:IUPAC-Name
n4:271B6227-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B622D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B622C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6229-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B622A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B622B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6225-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6223-363D-11E5-9242-09173F13E4C5 n4:271B6226-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6224-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B6233-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6234-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B622E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B622F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6231-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6230-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6232-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
59643-91-3
n3:Bioavailability
n4:271B6238-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B623A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B623B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6237-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6236-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6239-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6228-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6235-363D-11E5-9242-09173F13E4C5